ASM8: Completed Phase II enrollment

Pharmaxis completed enrollment of 16 adult asthmatics in a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial evaluating once-daily 3 and 7.8 mg ASM8 for 14 days. ...